BioCryst Pharmaceuticals Inc. Common Stock (BCRX)
Stock · NASDAQ · Health Care
$7.79as of 10/16/2026
Price chart
Active signals
BCRX Signal Track Record
How signals performed across all stocks →What BCRX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 36 | -0.9% | 50% | September 30, 2026 |
| Bollinger Band BreakdownActive now | 22 | +1.7% | 55% | September 8, 2026 |
| Bollinger Band Breakout | 22 | -4.6% | 41% | August 11, 2026 |
| 200-Day Moving Average TouchActive now | 6 | -7.7% | 17% | September 17, 2026 |
| Any 20-session window (baseline) | -1.3% | 45% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About BCRX
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is als…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 435
- Website
- www.biocryst.com/
Fundamentals
- 1-day range
- $7.74$8.02
- Market cap
- $2.36B
- P/E (trailing)
- —
- P/E (forward)
- 8.29
- EPS (trailing)
- $-1.50
- Dividend yield
- —
- Beta
- 0.54
- Avg. volume
- 4.12M
How BioCryst Pharmaceuticals Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
11 analyst ratings
BioCryst Pharmaceuticals Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- BCRXBioCryst Pharmaceuticals Inc. Common Stock$7.79▼ 2.87%Market cap $2.36BP/E —$6.23$11.22
- ADMAADMA Biologics Inc Common Stock$10.68▼ 0.47%Market cap $2.34BP/E 13.67$7.21$20.46
- VCELVericel Corporation Common Stock$40.13▼ 2.17%Market cap $2.29BP/E 85.09$28.95$49.32
- RVMDWRevolution Medicines Inc. Warrant$8.4▼ 13.98%Market cap $2.25BP/E —$0.2311$13.44
- MESOMesoblast Limited American Depositary Shares$13.28▼ 4.80%Market cap $2.02BP/E —$1.88$3.31
- IOVAIovance Biotherapeutics Inc. Common Stock$13.62▼ 7.47%Market cap $2.77BP/E —$1.76$15.3
- TARSTarsus Pharmaceuticals Inc. Common Stock$68.07▼ 4.11%Market cap $2.81BP/E —$53.89$91.53
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| BCRX BioCryst Pharmaceuticals Inc. Common Stock | $2.36B | — | $7.79 | ▼ 2.87% | $6.23$11.22 |
| ADMA ADMA Biologics Inc Common Stock | $2.34B | 13.67 | $10.68 | ▼ 0.47% | $7.21$20.46 |
| VCEL Vericel Corporation Common Stock | $2.29B | 85.09 | $40.13 | ▼ 2.17% | $28.95$49.32 |
| RVMDW Revolution Medicines Inc. Warrant | $2.25B | — | $8.4 | ▼ 13.98% | $0.2311$13.44 |
| MESO Mesoblast Limited American Depositary Shares | $2.02B | — | $13.28 | ▼ 4.80% | $1.88$3.31 |
| IOVA Iovance Biotherapeutics Inc. Common Stock | $2.77B | — | $13.62 | ▼ 7.47% | $1.76$15.3 |
| TARS Tarsus Pharmaceuticals Inc. Common Stock | $2.81B | — | $68.07 | ▼ 4.11% | $53.89$91.53 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and GrowthYahoo · 10/5/2026
- JP Morgan Maintains Neutral on BioCryst Pharma, Raises Price Target to $13Benzinga · 9/30/2026
- Claude AI Just Bought These 2 Pharma StocksYahoo · 9/29/2026
- Novo Nordisk: Capital Markets Day Reveals Its Next Growth EngineSeekingAlpha · 9/24/2026
- Is BioCryst’s (BCRX) Newest Approval Bigger Than It Looks?Yahoo · 9/23/2026
- Biopharma Stock With Layers of Technical Support in PlaceYahoo · 9/21/2026
- BioCryst Eyes $1B Rare-Disease Future Through External InnovationYahoo · 9/19/2026
- 4 Biotech Stocks to Watch as Potential Takeover TargetsYahoo · 9/18/2026
Insider Activity
Insider Actions →- Amy E. McKee · August 31, 2026 · Grant644 @ $9.7
- Jill C. Milne · August 31, 2026 · Grant1.3K @ $9.7
- Steven Frank · August 31, 2026 · Grant1.3K @ $9.7
- Jon P. Stonehouse · August 31, 2026 · Grant644 @ $9.7
- Vincent Milano · August 31, 2026 · Grant1.2K @ $9.7
- MacHelle Sanders · June 11, 2026 · Grant15.3K
- Jill C. Milne · June 11, 2026 · Grant33.5K
- Jill C. Milne · June 11, 2026 · Grant15.3K
- Amy E. McKee · June 11, 2026 · Grant33.5K
- Amy E. McKee · June 11, 2026 · Grant15.3K
- Theresa Heggie · June 11, 2026 · Grant33.5K
- Theresa Heggie · June 11, 2026 · Grant15.3K
- MacHelle Sanders · June 11, 2026 · Grant33.5K
- Steven Frank · June 11, 2026 · Grant33.5K
- Steven Frank · June 11, 2026 · Grant15.3K
Institutional Ownership
March 31, 2026
- Total shares held
- 232.86M
- Total value held
- $2.18B
- Institutional holders
- 291
- Unknown22.65M
- Unknown15.83M
- Unknown15.04M
- Unknown12.21M
- Unknown11.14M
- Unknown11.02M
- Unknown8.91M
- Unknown7.43M
- Unknown7.03M
- Unknown6.39M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
BCRX Trades at 11x Forward Earnings, Analysts See $20.73 Target
BCRX is currently trading at about 11 times its forward earnings, which is on the lower side for the biotech sector. Analysts have an average target of $20.73, with a range from $11 to $32, while the stock sits near the bottom of its 52‑week range. This valuation gap raises questions about whether the market is pricing in potential challenges for the company.
BCRX Trades at 11x Forward Earnings, Analysts See $20.73 Target. BCRX is currently trading at about 11 times its forward earnings, which is on the lower side for the biotech sector. Analysts have an average target of $20.73, with a range from $11 to $32, while the stock sits near the bottom of its 52‑week range. This valuation gap raises questions about whether the market is pricing in potential challenges for the company.